© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Pharmaceutical history tends to move forward on the back of unmet need and pragmatic trial. The story of Elagolix Sodium starts in the late 1990s, when researchers hunted for less invasive ways to manage chronic health issues tied to hormones, such as endometriosis and uterine fibroids. At that point, many saw surgical routes or older hormone drugs as the only viable choices, leaving real gaps for millions who needed daily function, not just symptom relief. Scientists at Neurocrine Biosciences saw evidence from earlier nonpeptide GnRH antagonists but ran into tangle after tangle, from poor bioavailability to safety flags. Work with structure-activity relationships, selectivity screens, and pharmacokinetic modeling set the stage for modifications that made Elagolix workable as an oral tablet. By 2010, pivotal clinical trials moved forward. FDA approval came later, marking a rare shift away from injectables and tough side effect tradeoffs that defined the prior decades.
Elagolix Sodium offers a window into how small tweaks in medical chemistry sometimes lead to radically better patient experience. As a nonpeptide, orally bioavailable GnRH receptor antagonist, this drug directly dampens pituitary stimulation and lowers estrogen, addressing both pain and bleeding from conditions like endometriosis or fibroids. With a well-validated dosing scheme and consistent absorption, it provides rapid suppression of hormone cycling without the irreversible effects that worried doctors in the past. In prescribing rooms, Elagolix earns marks for predictability, straightforward titration, and a safety label emphasizing reversible bone effects rather than permanent suppression or profound mood shifts.
A close look at Elagolix Sodium points to deliberate medicinal chemistry. Chemically, it features a sodium salt form for better solubility and absorption; it weighs in at roughly 923.1 g/mol as the sodium salt, with a melting point clocking in above 200°C. The compound remains stable at room temperature and resists hydrolysis in standard storage, which helps with shelf life. White to off-white in appearance, the drug is odorless and compact, making it easy to compress into tablets with good uniform distribution of active ingredient. Elagolix’s crystalline nature reflects careful crystallization steps, not just for purity, but for ensuring consistent pharmacological effect in each dose.
Regulatory files lay out exacting standards on every aspect of Elagolix Sodium’s composition and use. Tablets typically contain a measured amount of active pharmaceutical ingredient—either 150 mg for once-daily use or 200 mg for twice-daily dosing—blended with lactose, microcrystalline cellulose, and film coatings to speed release and ensure stability. Labels warn about bone mineral density loss and encourage periodic monitoring. Every container carries batch codes, expiration dates, and handling instructions to keep the product uncontaminated by moisture or sunlight during shipping and storage. The safety insert details routes of metabolism and excretion for physicians, but also offers language at the eighth-grade level for patients regarding common side effects and the need to avoid use in pregnancy.
The manufacture of Elagolix Sodium traces back through a series of practical, scalable chemical reactions. A starting base of substituted benzamides, carefully selected for steric and electronic properties, provides the molecular scaffold. Stepwise coupling reactions, including Suzuki and amidation pathways, attach pyrimidine derivatives. The final product comes through a sodium salt formation step, where the free acid reacts with sodium hydroxide under controlled conditions. Every stage demands analytical verification—NMR, mass spectrometry, and high-performance liquid chromatography confirm purity and lack of unwanted byproducts. Filtration, crystallization, and drying under vacuum yield a fine, pure powder ready for blending into tablets.
Medicinal chemists continually hunt for chemical structures that hit the sweet spot between biological potency, oral absorption, and resistance to unwanted metabolism. Elagolix’s backbone took shape from trial-and-error substitutions, where even subtle ring changes and alkyl additions altered hormone receptor binding and metabolic breakdown rates. Progress in this field refutes the idea of chemistry as mere recipe-following; it’s closer to gardening, tending each derivative to grow the desired compound. What sets Elagolix apart is the careful tuning of hydrogen-bonding groups and the sodium counterion, which together produce a tablet that’s absorbed within thirty minutes of ingestion yet avoids the liver toxicity that plagued earlier attempts. Its metabolism mostly runs through CYP3A enzymes, and minor tweaks can adapt the core structure to fine-tune how fast or slow the drug leaves the body, offering opportunities for future generations of similar medicines.
Across regulatory filings and global marketplaces, Elagolix Sodium answers to several synonyms. Researchers may refer to it as NBI-56418 or by its development code, ABT-620. The FDA-approved product name in the United States is Orilissa. In scientific literature, the IUPAC name—sodium (2S)-2-(hydroxymethyl)-2-[[4-[2-methoxy-2-oxoethyl]-3-[[2-methyl-3-[[3-(trifluoromethyl)phenyl]sulfonylamino]phenyl]methyl]pyridin-2(1H)-yl]carbamoyl]propanoate—gets quoted in technical documents but dropped in everyday clinic life. Pharmaceutical suppliers catalog the sodium salt under various stock numbers, enabling easier global distribution for research and development labs or hospitals.
Handling pharmaceutical intermediates requires more than lab coats and gloves; firms producing Elagolix Sodium stick by Current Good Manufacturing Practices to ensure worker and patient safety. Production areas separate allergenic excipients, enforce filtered air, and maintain strict documentation to allow recall if anything ever goes wrong. Final product testing screens for microbial contamination, residual solvents, and heavy metals—each possible threat gets tracked to below established FDA or EMA limits. On the patient side, safety standards call for periodic bone density monitoring, pregnancy exclusion signals, and liver function testing in those with pre-existing disease. Health workers learn to spot rare hypersensitivity cases and report any post-marketing surprises to pharmacovigilance databases, creating a feedback loop that tightens future quality controls.
Prescribing Elagolix Sodium today broadens what’s possible for women facing chronic, under-treated gynecological pain. It holds FDA approval for moderate to severe pain caused by endometriosis and for heavy menstrual bleeding due to uterine fibroids. For many patients, relief comes with the first week of use, as suppressed estrogen levels mean less tissue growth and lower inflammation. Unlike older drugs that produced full menopause or risked irreversible infertility, Elagolix offers dose flexibility and reversible ovarian suppression—one can dial pain control up or down as life circumstances shift. The quick onset and limited need for monitoring make it practical for use outside hospital centers, reaching a wider population. Off-label research explores its impact in conditions like polycystic ovary syndrome and certain hormonally driven cancers, but mainstream focus remains on its original approved uses.
Pharmacological innovation thrives when firms commit to rigorous, transparent clinical trials and open-ended exploration of new uses. Elagolix’s development saw years of animal studies, progressing through Phase 1 safety work, to larger, placebo-controlled trials that defined its clinical benefit and established optimal dose for both efficacy and safety. Published results in journals like the New England Journal of Medicine document not just reduced pain scores but sustained improvements in daily function—walking, working, intimacy—all hard-won gains for those with endometriosis or fibroids. Ongoing research continues to track bone density impacts and looks at using the drug in adolescent or perimenopausal groups. Preclinical scientists also tinker with the chemical scaffold for next-generation compounds that may offer longer action, fewer side effects, or different hormone modulation for conditions beyond gynecology.
Making new drugs without a clear view of safety is like building a bridge on foggy ground. Elagolix Sodium underwent extensive toxicity studies in both rodents and non-human primates, logging organ effects at high-dose ranges and chronic exposure. Main findings focused on the expected—bone density loss, which reversed on stopping the drug—and less common risks like liver enzyme elevation or shifts in cholesterol. Importantly, no mutagenicity or evident carcinogenic signal cropped up, supporting its approval for long-term treatment. Postmarketing data confirmed that rare allergic or psychiatric events can occur but remain manageable with good patient screening and follow-up. Recent studies continue to monitor how bone health evolves after drug cessation and track rare side effects in diverse populations.
Seeing Elagolix Sodium move from bench to bedside reminds us of the impact one innovation can have when persistent trial, interdisciplinary collaboration, and patient need align. The future looks bright, with planned studies in conditions poorly served by existing hormone modulators. Advances in medicinal chemistry may yield scaffold tweaks that protect bones or allow once-monthly dosing. Real-world data, captured by wearable sensors and electronic health records, will guide smarter dosing strategies based on individual need rather than averages. In the pipeline, new delivery routes—transdermal patches, long-acting injectables—may widen the circle of benefit. As the science deepens and access expands, the legacy of Elagolix will lie in pushing past the limits of what hormone modulating therapy can do for day-to-day living, not just disease.
Elagolix sodium enters the scene as a prescription medicine designed for women fighting two stubborn health issues: endometriosis pain and heavy periods caused by uterine fibroids. These conditions don’t just mess with comfort—they break daily routines, strain relationships, and eat away at quality of life for countless people. I’ve seen friends and colleagues make career and family sacrifices because of period pain or severe bleeding, watching them bounce from one treatment to the next with barely any relief.
The science is pretty direct. Elagolix sodium blocks a hormone signal in the brain that tells the ovaries to produce estrogen. Instead of wiping out estrogen altogether (the way some older drugs do), it lowers it a notch—enough to take some sting out of symptoms without creating endless hot flashes or bone loss that comes from shutting estrogen down completely. This careful balancing act means a person gets less pain and bleeding, but still hangs on to some hormones for bone and heart health.
Millions of women live with these conditions. Endometriosis affects about one in ten women during their reproductive years. Uterine fibroids show up in up to 70% of women by age fifty. Some women find mild relief with pain killers or birth control, but those approaches rarely work well for severe cases. People lose workdays and miss out on family events—not to mention the hit to self-esteem when pain becomes constant and unpredictable.
Surgery, like laparoscopy or hysterectomy, hangs over many patients’ heads as a last resort. Yet not everyone wants or can afford such invasive procedures. That’s the niche Elagolix sodium fills. It’s an oral tablet, taken once or twice a day. Suddenly, the person making endless doctor visits or stocking up on pads each week gets a chance to take back control—no hospital stay, no scalpel, fewer excuses for missing out on life.
Clinical studies show fewer days with pain, lighter periods, and better emotional health when women start taking Elagolix sodium. The FDA cleared it for use in the United States for endometriosis pain in 2018 and for heavy menstrual bleeding due to fibroids in 2020. For many, it’s a sigh of relief. Doctors finally have more tools beyond painkillers and surgery.
The road isn’t completely smooth. Side effects show up, including hot flashes and some risk of weaker bones after longer use. Insurance coverage depends on the person’s policy, and specialists sometimes face hurdles getting prescriptions approved for patients. This drug won’t erase the pain for everyone and shouldn’t be the only answer, especially long-term.
One piece sometimes missing from headlines: access. Women in rural areas or those without good prescription coverage still fall through the cracks. Knowledge gaps among doctors in primary care settings can delay diagnosis or treatment. To really open access, we need more community outreach, improved insurance coverage, and training for providers. Policies should support greater screening and awareness around these often silent health conditions. Drug makers, insurers, and advocacy groups working together create change that reaches further than a new pill—it means a better life on the other side of suffering.
Taking a medicine like Elagolix Sodium means accepting more than its promise. For people managing endometriosis or uterine fibroids, this drug offers relief from pain and symptoms that upend daily life. Yet, none of us want to swap one set of problems for another. Knowing what can happen after starting Elagolix can make a real difference in how folks approach their treatment, talk with their healthcare teams, and care for themselves.
Hot flashes top the list, much like they do for women in menopause. I remember my friend, diagnosed with endometriosis, complaining about a rush of heat hitting her in the middle of meetings. It left her embarrassed, fanning herself and wishing for an open window. Night sweats go hand in hand. These changes stem from the way Elagolix tampers with hormone levels—by knocking down estrogen, it signals the body in ways that trigger these reactions.
Headaches often follow. For some, this means a steady throb that drags through the day—not quite enough to send them to bed, but just persistent enough to make work and home life more difficult. Fatigue also creeps in. It’s not the kind that disappears after a good night’s sleep. Instead, people describe a fog or heaviness, like wading through water just to keep up.
Then there’s the emotional toll. Mood swings and irritability hit some users hard. My own sister, after months on hormone-targeting medicine, said she felt like a stranger in her own skin—snap judgments, tears that didn’t make sense, worry that arrived out of nowhere. Science echoes these stories. A 2018 clinical trial published in "The New England Journal of Medicine" links Elagolix to higher rates of mood changes, even in women with no depression in their past.
Menstrual changes can catch people off guard, too. Irregular periods or lighter bleeding start soon after treatment begins. For women who have spent years tracking cycles to predict pain or fertility, this break in the pattern can become stressful, even if less bleeding offers relief.
Bone loss deserves close attention. Lowering estrogen comes with real costs. Estrogen strengthens bones; take it away, bones become brittle. Women who take Elagolix long term should know that their bones might thin out. Dexa scans—a quick bone density test—offer a way to check on this risk. My neighbor, who started Elagolix for fibroids, ended up with regular bone monitoring in her care plan.
For most, side effects sound scarier in theory than in daily life. Many will experience just a handful. Still, talking with a doctor before starting Elagolix pays off. Share your family history. Ask about ways to manage hot flashes or trackers for mood changes. Take calcium and vitamin D if your diet falls short. Weigh the tradeoffs honestly. No treatment covers all bases or fits every person.
The bigger lesson: medicine never lives in isolation. Staying alert to your body’s signals, keeping records of how you feel, and counting on good communication with health professionals goes a long way. The choice belongs with you, guided by clear facts, mutual trust, and thoughtful support from people who understand what you’re up against. There’s strength in tuning in, speaking up, and taking charge of your care.
Anyone who deals with endometriosis pain knows how exhausting it can be. Doctors sometimes prescribe Elagolix Sodium to manage that pain. Reading a clinical paper is one thing, but hearing from someone who’s taken it cuts through a lot of noise. If a pill can give people back more comfortable days, you want to do things right. Here’s what actual use, good evidence, and sound advice say about taking Elagolix Sodium sensibly.
Doctors usually suggest a rhythm for this medication: take it exactly as prescribed, no skipping and no creative timing. Science shows keeping consistent levels of Elagolix Sodium in the body helps block those hormones feeding endometriosis symptoms. If you take it at a different time every day, your body has to play catch-up—all that does is bring back the pain and mess with the treatment's success.
With Elagolix Sodium, timing and food don’t matter much—it works just fine on a full or empty stomach. Still, a stubborn stomach or nausea can get in the way, especially in the first week. I found taking it with a light snack kept things steady. Reputable sources like Mayo Clinic agree that you can eat as normal, but keeping a daily routine helps prevent skipped doses.
Missing one pill isn’t the end of the world, but it’s best to take it as soon as you remember. If you’re too close to the next scheduled dose, don’t double up. Too much Elagolix Sodium can lead to serious side effects, including hot flashes or changes in mood. If someone takes more than recommended, call a local poison center or healthcare provider right away. This isn’t a medication to mess around with.
Doctors check a person’s history before writing out Elagolix Sodium because it can lower bone density. Anyone with osteoporosis in the family or vitamin D deficiencies should talk this over before starting. Regular blood work and bone scans aren’t just formalities—they give peace of mind and flag problems before they get out of hand.
It’s tempting to read stories online and tweak treatment based on someone else’s experience. Every body handles hormones differently. Trusting your own doctor and reporting any odd side effects, from mood changes to new pain or heavy bleeding, makes all the difference. Reliable research—including FDA and academic sources—backs up that open communication leads to better outcomes.
Keeping pills in the same spot and linking them to a daily routine—after brushing teeth or before breakfast—helps everyone stay on course. Reminders on a phone or a sticky note on the fridge take the guesswork out of it. Bringing up any trouble at follow-up visits gives your doctor a chance to offer solutions, especially if pain flares up or periods get heavier.
Elagolix Sodium doesn’t solve every problem overnight. Staying honest with yourself, keeping up with prescriptions, and talking frankly with healthcare teams lead to real progress. No one benefits from secrets or shortcuts. Respecting your health means respecting the plan—one dose at a time.
Elagolix sodium is a prescription medicine mainly offered to help women manage pain connected to endometriosis. Doctors use it to dial down hormones that fuel endometriosis symptoms. Plenty of women find relief, but not everyone gets to benefit from this drug. Some folks face more risk than reward if they take it.
One of the most common reasons doctors steer clear of elagolix sodium involves liver issues. If the liver does not work well, elagolix sodium tends to stick around too long. That raises the risk of side effects. Anyone with severe liver problems should avoid this medicine. I’ve seen people shrug off liver issues, hoping for quick relief, only to wind up in worse shape than before.
No one hands elagolix sodium to women who are pregnant or planning pregnancy. This drug reduces estradiol, a key player in reproductive health. It can cause harm to a developing baby. I know women who planned for a family and carefully weighed every medication. Taking elagolix sodium during pregnancy is a clear red flag—there’s a real risk for birth defects or even pregnancy loss.
There’s another catch. Elagolix sodium takes a bite out of estrogen, leading to lower bone density. That’s not a small problem. Young women who already deal with low bone mass, frequent bone breaks, or have a family history of osteoporosis, should pause and talk to their doctor. None of us want to swap pain now for brittle bones tomorrow. Those with a record of unexplained vaginal bleeding should highlight that detail; elagolix sodium can make things worse or hide deeper health issues.
Mixing elagolix sodium with other medicines brings a long list of possible clashes. People taking cyclosporine or gemfibrozil, for instance, risk higher levels of elagolix sodium in their system. Both drugs can overload key enzymes in the liver that process medications. That means higher odds of side effects. Anyone taking ritonavir or hormonal birth control pills should get clear guidance, not just guesswork. These possible mishaps highlight why every new medicine deserves a thorough check-in with the pharmacist or doctor.
Doctors don’t hand out elagolix sodium as a simple fix for every case of endometriosis. The right match includes checking medical records, reviewing other prescriptions, and asking honest questions about long-term health goals. Health often gets shaped by the small print most of us ignore. If you’re considering elagolix sodium, come prepared with facts about your history. Mention past bone problems, liver tests, any medicines you’re taking—even if the truth feels small or embarrassing. That detail might spare months or years of regret.
The conversation about risks isn’t only on the doctor’s shoulders. Patients have the right to review front and back of the prescription. Ask why this drug beats others for your pain. Dig for information about lifestyle changes that give relief—exercise, nutrition, or non-hormonal treatments. If things look complicated, consider a second opinion. Better safe than sorry with medicine that affects so many organs and systems. In the end, health decisions work out best with honest talk, facts on the table, and a focus on long-term care, not just quick fixes.
Mixing drugs sometimes feels like playing a risky game. A small prescription can make everything fine or cause unexpected trouble if it clashes with something else in your daily lineup. Elagolix Sodium, a pill widely prescribed for endometriosis and uterine fibroids, landed in medicine cabinets pretty recently. People started asking about interactions because missing a detail can send you straight back to the doctor’s office.
Elagolix works by hitting hormone signals—specifically, it slows the brain’s call for gonadotropin hormones. That’s a big deal when dealing with hormone-driven conditions. Now, the body processes Elagolix through a liver route called CYP3A, a system busy with lots of other medication traffic.
I once watched a pharmacist spend ten minutes double-checking a list of painkillers, sleep aids, and allergy tablets for someone on Elagolix. That’s because any drug blocking or boosting CYP3A can mess with Elagolix’s effects.
Ask about strong CYP3A inhibitors like ketoconazole or itraconazole—they raise Elagolix levels and can cause more side effects. On the other side, CYP3A inducers such as rifampin or carbamazepine rush the body to clear out Elagolix too fast. Neither situation helps people trying to keep hormone problems under control.
Consider birth control pills. Estrogen-based ones don’t play nicely with Elagolix because hormone levels shift. It can mean less protection or extra side effects like hot flashes and night sweats—definitely not what anyone hopes for.
Several clinical studies and FDA records highlight key findings: drugs like digoxin and rosuvastatin might show up more in the bloodstream when taken with Elagolix, since it may impact certain drug transporters in the liver. If you’re carrying a prescription for those, doctors usually want extra blood tests to spot changes before they become a headache.
People who take corticosteroids or anti-seizure medications should always bring it up. Liver pathways can tangle easily, and missing those problem interactions means risking higher side effects, lower drug success, or both. Even some herbal products, especially St. John’s Wort, can throw everything off balance.
Doctors and pharmacists hold a lot of keys to safe drug combos, but patients play an equal part. Write down every pill or supplement. Share the list whenever you head to a new appointment. Skipping this step opens the door to interactions. Labs exist for a reason—blood tests and liver function checks really do spot trouble before it starts. Pharmacies keep electronic records for interaction alerts, so filling everything in one location pays off.
People trusting online health forums for advice sometimes miss key steps that could wreck careful long-term management. Sticking to professional sources matters. Reading the medication guide at each refill helps—the paper in the box highlights new risks or medicine recalls.
No two bodies process medicine exactly the same way. Personalized medicine could smooth out some bumps with genetic testing—but for now, tracking symptoms and checking in with pros comes first. Medical technology keeps advancing, but human transparency wins every time. Open conversation makes all the difference when drugs share the same stage in the body.
| Names | |
| Preferred IUPAC name | sodium;4-[[6,7-dimethoxy-3-(2-methoxy-2-methylpropyl)-1,2,3,4-tetrahydroisoquinolin-2-yl]methyl]benzonitrile |
| Other names |
ABT-620 ORILISSA NBI-56418 |
| Pronunciation | /ɛˈlæɡəˌlɪks ˈsoʊdiəm/ |
| Identifiers | |
| CAS Number | 832720-36-2 |
| Beilstein Reference | 14300462 |
| ChEBI | CHEBI:134722 |
| ChEMBL | CHEMBL3544940 |
| ChemSpider | 128800 |
| DrugBank | DB14509 |
| ECHA InfoCard | 100.246.479 |
| EC Number | EC 248-251-4 |
| Gmelin Reference | 1140503 |
| KEGG | D11273 |
| MeSH | D000068875 |
| PubChem CID | 125173553 |
| RTECS number | XN7VBG669G |
| UNII | DN45I5MJ2V |
| UN number | UN number not assigned |
| Properties | |
| Chemical formula | C32H29F2N3Na2O5S |
| Molar mass | 867.97 g/mol |
| Appearance | White to off-white solid powder |
| Odor | Odorless |
| Density | 1.3 g/cm^3 |
| Solubility in water | Freely soluble in water |
| log P | -1.2 |
| Acidity (pKa) | 13.68 |
| Basicity (pKb) | pKb = 2.74 |
| Magnetic susceptibility (χ) | NA |
| Dipole moment | 4.72 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 527.3 J mol⁻¹ K⁻¹ |
| Pharmacology | |
| ATC code | G03XB03 |
| Hazards | |
| Main hazards | May damage fertility. Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS labelling: Danger; H302, H315, H319, H335, H360; P261, P264, P280, P301+P312, P305+P351+P338, P308+P313 |
| Pictograms | HCPCS | GPI | RxCUI | UNII | KEGG | ChEBI | ChEMBL | DrugBank | PubChem --- | --- | --- | --- | --- | --- | --- | --- | --- J3490 | 52409590002020 | 1995209 | 3T2J6C51XV | D10587 | 142555 | CHEMBL2105723 | DB14540 | 46216610 |
| Signal word | Warning |
| Hazard statements | H360: May damage fertility or the unborn child. |
| Precautionary statements | May damage fertility or the unborn child. |
| NFPA 704 (fire diamond) | Health: 2, Flammability: 1, Instability: 0, Special: - |
| LD50 (median dose) | > 5000 mg/kg (rat, oral) |
| PEL (Permissible) | Not established |
| REL (Recommended) | 300 mg daily |
| IDLH (Immediate danger) | Not Established |
| Related compounds | |
| Related compounds |
Elagolix Alogliptin Deslorelin Degarelix Relugolix |
